Stocks | | | Some of the most popular dividend-paying stocks are known as dividend aristocrats. Aristocrats are basically people that are known for being the best and noblest in all of the land, so associating that word with stocks has significant power. Read the Full Story |
|
From Our Partners | | Washington is running out of money…And guess where they'll look next?
When governments go broke, they take from the people.
It's happened before, and it's happening again.
The Department of Justice just admitted that cash isn't legally YOUR property. | | Get your free guide now by clicking here >> |
|
Stocks | | | Industrials Will Lead The Market In 2020
With the end of the year just around the corner, it’s past time to think about positioning for 2020. When it comes to earnings power in 2020, the Industrial sector is going to be the market leader and that is where I like my money to be. To be clear, w... Read the Full Story |
|
Markets | | | The Labor Market Is Driving Our Economy And Coming To A Boil
The labor markets were one of the most closely watched segment of our economy in 2019. Despite all the naysaying, the labor market ended the year on the most solid footing its been on in the history of the U.S. The size of the labor force... Read the Full Story |
|
From Our Partners | | How to Collect Up To $5,917/mo From Trump's Made In USA Boom
Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America.
But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month.
Don't miss your chance to participate directly in America's industrial comeback. | | Watch Now to Learn How to Get Your First Check in 30 Days |
|
Markets | | |
It's one of the biggest tech stocks there is, and a come-from-behind underdog that turned into a behemoth over the course of the 2010s. It's fundamentally shaken up not only technology, but the arts as well, and even the entire field of e-commerce owes a lot to it. It's Apple (NASDAQ:AAPL), and it... Read the Full Story |
|
Stocks | | |
It could be forgiven, that some might think that Tesla (NASDAQ: TSLA) was little more than a big pile of pie-in-the-sky nonsense. Yet it seems, these days, that we hear a lot of positive buzz around this maker of electric vehicles that implores we take this company seriously. One more brick in the... Read the Full Story |
|
From Our Partners | | Cold War Discovery Could Unlock $100 Trillion in Wealth
Jeff recently traveled to an American ghost town to investigate this crazy Cold War story…
Because it could hold the key to the entire $100 trillion AI boom.
It involves an American ghost town with just 30 people…
And a new twist to the AI boom that could make a lot of people rich. | | Click here to see the details on what could be the biggest tech story of this decade. |
|
The Early Bird Stock Of The Day Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. | | View Today's Stock Pick |
|
